Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 102

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 102
---
 is also more challenging. Uptake depends on alignment with established treatment paradigms, pricing relative to existing regimens,
and reimbursement policies. Physicians may hesitate to adopt combinations unless clear superiority in outcomes is demonstrated.

IP Protection.

The ATI Receptor Blockers technology is covered
by patent applications listed below, which, subject to our exercising our option to obtain the license, will be the subject of an exclusive
to us by Yissum.

Title: Liposomal Formulations Comprising AT1 Receptor Blockers (ARB) and Uses Thereof (Composition matter and use claimed)

| ** | Note:                                                                                     
 this application was abandoned and divisional application in CN was filed. The divisional 
 has not been published yet (as of Sept 20th, 2025)                                        |

<div align='center'>66</div>

References:

| 1. | Keith SW, Gerber DE, Raghavan D, Galsky MD, Lin J, Wang L, et                                   
 al. Angiotensin blockade therapy and survival in pancreatic cancer. BMC Cancer. 2022;22(1):920. 
 doi:10.1186/s12885-022-09200-4                                                                  |

| 2. | Nakai Y, Isayama H, Ijichi H, Sasaki T,                                                       
 Kogure H, Yagioka H, Yamamoto K, Arizumi T, Hamada S, Miyabayashi K, Mizuno S, Kawakubo K,    
 Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K. Phase I trial of gemcitabine   
 and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: 
 GECA1. Cancer Science. 2012;103(8):1489-92. doi:10.1111/j.1349-7006.2012.02311.x              |

| 3. | Wilop S, von Hobe S, Crysandt M, Esser A,                                                  
 Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II  
 type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer  
 undergoing first-line platinum-based chemotherapy. Journal of Cancer Research and Clinical 
 Oncology. 2009;135(10):1429–1435. doi:10.1007